- Management of Non-pain Symptoms in Terminally Ill Cancer Patients: Based on National Comprehensive Cancer Network Guidelines
-
Lee HR
- KMID: 2305294
- Korean J Hosp Palliat Care.
- 2013 Dec;16(4):205-215.
- doi: 10.14475/kjhpc.2013.16.4.205
Most terminally ill cancer patients experience various physical and psychological symptoms during their illness. In addition to pain, they commonly suffer from fatigue, anorexia-cachexia syndrome, nausea, vomiting and dyspnea. In... -
- CITED
-
- Close
- SHARE
-
- Close
- 3,4,5-Trihydroxycinnamic Acid Inhibits Lipopolysaccharide-Induced Inflammatory Response through the Activation of Nrf2 Pathway in BV2 Microglial Cells
-
Lee JW, Choi YJ, Park JH, Sim JY, Kwon YS, Lee HJ, Kim SS, Chun W
- KMID: 2170687
- Biomol Ther.
- 2013 Jan;21(1):60-65.
3,4,5-Trihydroxycinnamic acid (THC) is a derivative of hydroxycinnamic acids, which have been reported to possess a variety of biological properties such as anti-inflammatory, anti-tumor, and neuroprotective activities. However, biological activity... -
- CITED
-
- Close
- SHARE
-
- Close
- 3,4,5-Trihydroxycinnamic Acid Inhibits LPS-Induced iNOS Expression by Suppressing NF-kappaB Activation in BV2 Microglial Cells
-
Lee JW, Bae CJ, Choi YJ, Kim SI, Kim NH, Lee HJ, Kim SS, Kwon YS, Chun W
- KMID: 2071755
- Korean J Physiol Pharmacol.
- 2012 Apr;16(2):107-112.
- doi: 10.4196/kjpp.2012.16.2.107
Although various derivatives of caffeic acid have been reported to possess a wide variety of biological activities such as neuronal protection against excitotoxicity and anti-inflammatory property, the biological activity of... -
- CITED
-
- Close
- SHARE
-
- Close
- Functional Role of Serine Residues of Transmembrane Dopamin VII in Signal Transduction of CB2 Cannabinoid Receptor
-
Rhee MH
- KMID: 1095120
- J Vet Sci.
- 2002 Sep;3(3):185-191.
Using site-directed mutagenesis technique, I have replaced serine 285 and serine 292 with the alanine, and assessed the binding of agonist and signaling such as the inhibition of adenylyl cyclase... -
- CITED
-
- Close
- SHARE
-
- Close
